NCT00560560View on ClinicalTrials.gov

Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments

PHASE2CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Colorectal Neoplasm
Interventions
BIOLOGICAL

CP-751, 871

Human IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops.

Trial Locations (12)

41013

Pfizer Investigational Site, Seville

75246

Pfizer Investigational Site, Dallas

94115

Pfizer Investigational Site, San Francisco

03202

Pfizer Investigational Site, Elche

08003

Pfizer Investigational Site, Barcelona

08907

Pfizer Investigational Site, L'Hospitalet de Llobregat

PE3 6DA

Pfizer Investigational Site, Peterborough

Pfizer Investigational Site, Peterborough

LE1 5WW

Pfizer Investigational Site, Leicester

CF14 2TL

Pfizer Investigational Site, Cardiff

G12 0YN

Pfizer Investigational Site, Glasgow

SO16 6YD

Pfizer Investigational Site, Southampton

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY